Concepts (198)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Combined Chemotherapy Protocols | 20 | 2024 | 2552 | 1.260 |
Why?
|
| Breast Neoplasms | 18 | 2024 | 3000 | 1.220 |
Why?
|
| Pyridines | 8 | 2021 | 315 | 1.180 |
Why?
|
| Kidney Neoplasms | 7 | 2019 | 635 | 0.850 |
Why?
|
| Receptor, ErbB-2 | 7 | 2024 | 245 | 0.800 |
Why?
|
| Antineoplastic Agents | 8 | 2018 | 2411 | 0.750 |
Why?
|
| Carcinoma, Renal Cell | 5 | 2019 | 435 | 0.660 |
Why?
|
| Triple Negative Breast Neoplasms | 4 | 2024 | 152 | 0.650 |
Why?
|
| Neoadjuvant Therapy | 8 | 2024 | 373 | 0.640 |
Why?
|
| Benzenesulfonates | 2 | 2008 | 66 | 0.590 |
Why?
|
| Enzyme Inhibitors | 2 | 2007 | 645 | 0.440 |
Why?
|
| Carcinoma, Small Cell | 2 | 2017 | 133 | 0.420 |
Why?
|
| Comparative Effectiveness Research | 1 | 2012 | 53 | 0.410 |
Why?
|
| Lung Neoplasms | 5 | 2018 | 2347 | 0.410 |
Why?
|
| Prostatic Neoplasms | 5 | 2022 | 1768 | 0.400 |
Why?
|
| Capecitabine | 3 | 2021 | 98 | 0.380 |
Why?
|
| Bevacizumab | 8 | 2022 | 287 | 0.370 |
Why?
|
| Neoplasms | 6 | 2023 | 3035 | 0.360 |
Why?
|
| Students, Medical | 3 | 2023 | 418 | 0.350 |
Why?
|
| Chemotherapy, Adjuvant | 5 | 2024 | 485 | 0.350 |
Why?
|
| Radiosurgery | 3 | 2021 | 280 | 0.350 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2016 | 833 | 0.350 |
Why?
|
| Medical Oncology | 3 | 2019 | 382 | 0.340 |
Why?
|
| Middle Aged | 29 | 2024 | 25863 | 0.340 |
Why?
|
| Receptors, Estrogen | 3 | 2024 | 393 | 0.330 |
Why?
|
| Anilides | 3 | 2019 | 48 | 0.330 |
Why?
|
| Aged | 25 | 2024 | 19077 | 0.320 |
Why?
|
| Aged, 80 and over | 16 | 2021 | 6777 | 0.320 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2018 | 1114 | 0.310 |
Why?
|
| Receptors, Progesterone | 2 | 2019 | 174 | 0.300 |
Why?
|
| Humans | 47 | 2024 | 89063 | 0.290 |
Why?
|
| Prostatectomy | 2 | 2021 | 476 | 0.290 |
Why?
|
| Bone Neoplasms | 2 | 2019 | 329 | 0.280 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2006 | 72 | 0.280 |
Why?
|
| Female | 32 | 2024 | 46011 | 0.270 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2007 | 307 | 0.270 |
Why?
|
| Neoplasm Staging | 9 | 2023 | 2001 | 0.260 |
Why?
|
| Pyrroles | 2 | 2017 | 187 | 0.260 |
Why?
|
| Education, Medical, Undergraduate | 2 | 2019 | 178 | 0.250 |
Why?
|
| Indoles | 2 | 2017 | 312 | 0.250 |
Why?
|
| Neutropenia | 3 | 2021 | 216 | 0.250 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2024 | 1363 | 0.240 |
Why?
|
| Nitriles | 3 | 2024 | 160 | 0.240 |
Why?
|
| Trastuzumab | 2 | 2021 | 71 | 0.230 |
Why?
|
| Adult | 20 | 2024 | 26507 | 0.230 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2021 | 604 | 0.220 |
Why?
|
| Aspirin | 1 | 2024 | 159 | 0.220 |
Why?
|
| Watchful Waiting | 2 | 2022 | 63 | 0.220 |
Why?
|
| Piperazines | 2 | 2021 | 283 | 0.220 |
Why?
|
| Androgen Antagonists | 2 | 2021 | 154 | 0.210 |
Why?
|
| Vegetables | 2 | 2020 | 47 | 0.210 |
Why?
|
| Interdisciplinary Studies | 2 | 2019 | 20 | 0.200 |
Why?
|
| Disease-Free Survival | 6 | 2024 | 1214 | 0.200 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2024 | 242 | 0.200 |
Why?
|
| ErbB Receptors | 1 | 2005 | 500 | 0.200 |
Why?
|
| Schools, Medical | 2 | 2023 | 134 | 0.200 |
Why?
|
| Oxazoles | 1 | 2021 | 18 | 0.200 |
Why?
|
| Clinical Competence | 2 | 2018 | 780 | 0.200 |
Why?
|
| Double-Blind Method | 5 | 2024 | 1714 | 0.190 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2023 | 121 | 0.190 |
Why?
|
| Oncologists | 1 | 2021 | 36 | 0.190 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2021 | 156 | 0.190 |
Why?
|
| Postmenopause | 2 | 2024 | 102 | 0.190 |
Why?
|
| Triazoles | 2 | 2024 | 102 | 0.180 |
Why?
|
| Urologic Neoplasms | 1 | 2021 | 82 | 0.180 |
Why?
|
| Male | 20 | 2023 | 42251 | 0.180 |
Why?
|
| Quinazolines | 1 | 2021 | 221 | 0.170 |
Why?
|
| Leukemia | 1 | 2022 | 323 | 0.170 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2020 | 202 | 0.170 |
Why?
|
| Testosterone | 1 | 2021 | 275 | 0.170 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2020 | 244 | 0.160 |
Why?
|
| Neoplasm Metastasis | 4 | 2016 | 1108 | 0.160 |
Why?
|
| Palliative Medicine | 1 | 2018 | 11 | 0.160 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2019 | 128 | 0.160 |
Why?
|
| Diet | 2 | 2022 | 442 | 0.160 |
Why?
|
| Age Factors | 1 | 2023 | 1867 | 0.160 |
Why?
|
| Counseling | 1 | 2020 | 163 | 0.150 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2021 | 315 | 0.150 |
Why?
|
| Prospective Studies | 5 | 2023 | 4273 | 0.150 |
Why?
|
| Survival Analysis | 4 | 2021 | 1533 | 0.150 |
Why?
|
| Niacinamide | 2 | 2008 | 116 | 0.150 |
Why?
|
| Disease Progression | 5 | 2021 | 1488 | 0.150 |
Why?
|
| Phenylurea Compounds | 2 | 2008 | 114 | 0.140 |
Why?
|
| Biomarkers, Tumor | 2 | 2020 | 1543 | 0.140 |
Why?
|
| Carboplatin | 4 | 2022 | 304 | 0.140 |
Why?
|
| Cyclooxygenase 2 | 1 | 2017 | 99 | 0.140 |
Why?
|
| Paclitaxel | 4 | 2022 | 479 | 0.140 |
Why?
|
| Treatment Outcome | 8 | 2023 | 8203 | 0.140 |
Why?
|
| Curriculum | 2 | 2019 | 567 | 0.140 |
Why?
|
| Survival Rate | 5 | 2019 | 1889 | 0.140 |
Why?
|
| Health Services Misuse | 1 | 2016 | 19 | 0.140 |
Why?
|
| Patient-Centered Care | 1 | 2019 | 207 | 0.140 |
Why?
|
| Prognosis | 5 | 2023 | 3773 | 0.140 |
Why?
|
| Antibodies, Monoclonal | 2 | 2021 | 1400 | 0.140 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2008 | 3443 | 0.140 |
Why?
|
| Follow-Up Studies | 5 | 2024 | 3657 | 0.130 |
Why?
|
| Needs Assessment | 1 | 2016 | 157 | 0.130 |
Why?
|
| Education, Medical, Graduate | 1 | 2018 | 390 | 0.120 |
Why?
|
| Pediatrics | 1 | 2018 | 352 | 0.120 |
Why?
|
| Area Under Curve | 2 | 2018 | 337 | 0.110 |
Why?
|
| Molecular Targeted Therapy | 2 | 2016 | 285 | 0.110 |
Why?
|
| Adenocarcinoma | 1 | 2020 | 1194 | 0.110 |
Why?
|
| Intensive Care Units | 1 | 2016 | 395 | 0.110 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 848 | 0.100 |
Why?
|
| Quality of Life | 4 | 2022 | 1662 | 0.100 |
Why?
|
| Hospitalization | 1 | 2016 | 876 | 0.090 |
Why?
|
| Sirolimus | 1 | 2012 | 170 | 0.090 |
Why?
|
| Fatigue | 3 | 2017 | 179 | 0.090 |
Why?
|
| Young Adult | 4 | 2024 | 6288 | 0.080 |
Why?
|
| Clinical Trials as Topic | 2 | 2021 | 1149 | 0.080 |
Why?
|
| Combined Modality Therapy | 2 | 2023 | 1710 | 0.080 |
Why?
|
| Internship and Residency | 1 | 2018 | 1041 | 0.080 |
Why?
|
| Placebos | 1 | 2008 | 214 | 0.080 |
Why?
|
| Oncogenes | 1 | 2007 | 92 | 0.070 |
Why?
|
| Gadolinium DTPA | 1 | 2008 | 264 | 0.070 |
Why?
|
| Prostate-Specific Antigen | 2 | 2020 | 359 | 0.070 |
Why?
|
| Pandemics | 2 | 2023 | 771 | 0.070 |
Why?
|
| Deoxycytidine | 2 | 2021 | 238 | 0.070 |
Why?
|
| Cell Cycle | 1 | 2007 | 509 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2019 | 865 | 0.060 |
Why?
|
| Thrombocytopenia | 2 | 2017 | 187 | 0.060 |
Why?
|
| United States | 3 | 2024 | 6955 | 0.060 |
Why?
|
| Ki-67 Antigen | 1 | 2024 | 66 | 0.060 |
Why?
|
| Drug Administration Schedule | 2 | 2016 | 894 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2023 | 2863 | 0.060 |
Why?
|
| Canada | 1 | 2024 | 208 | 0.060 |
Why?
|
| Risk Factors | 3 | 2020 | 5466 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 859 | 0.060 |
Why?
|
| Abiraterone Acetate | 1 | 2023 | 12 | 0.060 |
Why?
|
| Contrast Media | 1 | 2008 | 1090 | 0.060 |
Why?
|
| Administration, Oral | 1 | 2024 | 682 | 0.050 |
Why?
|
| Cancer Survivors | 1 | 2024 | 95 | 0.050 |
Why?
|
| Prednisone | 1 | 2023 | 258 | 0.050 |
Why?
|
| Mastectomy, Segmental | 1 | 2023 | 101 | 0.050 |
Why?
|
| Time Factors | 2 | 2021 | 5320 | 0.050 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2023 | 296 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 2612 | 0.050 |
Why?
|
| Ipilimumab | 1 | 2021 | 61 | 0.050 |
Why?
|
| Radiation Oncologists | 1 | 2021 | 14 | 0.050 |
Why?
|
| Breast | 1 | 2023 | 292 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2023 | 9003 | 0.050 |
Why?
|
| Patient Care Planning | 1 | 2021 | 83 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2022 | 181 | 0.050 |
Why?
|
| Ferredoxin-NADP Reductase | 1 | 2020 | 15 | 0.050 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2020 | 27 | 0.040 |
Why?
|
| Perception | 1 | 2021 | 178 | 0.040 |
Why?
|
| Learning | 1 | 2023 | 285 | 0.040 |
Why?
|
| Telephone | 1 | 2020 | 35 | 0.040 |
Why?
|
| Hypertension | 2 | 2017 | 741 | 0.040 |
Why?
|
| Mastectomy | 1 | 2021 | 245 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 2019 | 270 | 0.040 |
Why?
|
| Health Personnel | 1 | 2021 | 212 | 0.040 |
Why?
|
| Cisplatin | 1 | 2021 | 617 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 2021 | 364 | 0.040 |
Why?
|
| Prostate | 1 | 2022 | 393 | 0.040 |
Why?
|
| Training Support | 1 | 2018 | 23 | 0.040 |
Why?
|
| Tamoxifen | 1 | 2019 | 168 | 0.040 |
Why?
|
| Consolidation Chemotherapy | 1 | 2018 | 23 | 0.040 |
Why?
|
| Hemoptysis | 1 | 2018 | 24 | 0.040 |
Why?
|
| Radiation Pneumonitis | 1 | 2018 | 21 | 0.040 |
Why?
|
| Interprofessional Relations | 1 | 2019 | 122 | 0.040 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2017 | 33 | 0.040 |
Why?
|
| Germ-Line Mutation | 1 | 2020 | 344 | 0.040 |
Why?
|
| Celecoxib | 1 | 2017 | 31 | 0.040 |
Why?
|
| Dinoprostone | 1 | 2017 | 70 | 0.040 |
Why?
|
| Pemetrexed | 1 | 2017 | 76 | 0.040 |
Why?
|
| Platinum Compounds | 1 | 2017 | 31 | 0.040 |
Why?
|
| Mucositis | 1 | 2017 | 18 | 0.040 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2021 | 395 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2018 | 272 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2017 | 69 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2014 | 967 | 0.040 |
Why?
|
| Educational Measurement | 1 | 2019 | 231 | 0.040 |
Why?
|
| Drug Eruptions | 1 | 2017 | 34 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2018 | 306 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2007 | 3373 | 0.030 |
Why?
|
| Maintenance Chemotherapy | 1 | 2017 | 84 | 0.030 |
Why?
|
| Selection Bias | 1 | 2016 | 37 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2018 | 684 | 0.030 |
Why?
|
| Anemia | 1 | 2017 | 129 | 0.030 |
Why?
|
| Standard of Care | 1 | 2016 | 65 | 0.030 |
Why?
|
| Transcriptome | 1 | 2020 | 628 | 0.030 |
Why?
|
| Genotype | 1 | 2020 | 1848 | 0.030 |
Why?
|
| Terminal Care | 1 | 2016 | 137 | 0.030 |
Why?
|
| Biomarkers | 1 | 2021 | 1755 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2014 | 299 | 0.030 |
Why?
|
| Incidence | 1 | 2018 | 1592 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2014 | 298 | 0.030 |
Why?
|
| Biopsy | 1 | 2017 | 1182 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2020 | 2290 | 0.030 |
Why?
|
| Remission Induction | 1 | 2014 | 740 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2020 | 2399 | 0.020 |
Why?
|
| MicroRNAs | 1 | 2016 | 551 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 1940 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2011 | 561 | 0.020 |
Why?
|
| Child | 1 | 2018 | 7149 | 0.020 |
Why?
|
| Chicago | 1 | 2011 | 1423 | 0.020 |
Why?
|
| Mutation | 1 | 2012 | 4132 | 0.010 |
Why?
|